Biogen Backs Down From M&A
This article was originally published in Scrip
Executive Summary
Biogen Inc. wouldn't acknowledge rumors that it plans to sell its hemophilia business, but CEO George Scangos told analysts during a first quarter earnings call that the big biotech will be focusing on "cost control" and keeping its head down.